Insider Buying: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) SVP Purchases 5,805 Shares of Stock

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) SVP Martin E. Cearnal purchased 5,805 shares of the business’s stock in a transaction that occurred on Monday, May 17th. The stock was acquired at an average price of $2.83 per share, with a total value of $16,428.15. Following the purchase, the senior vice president now owns 148,814 shares in the company, valued at $421,143.62. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Martin E. Cearnal also recently made the following trade(s):

  • On Friday, May 7th, Martin E. Cearnal acquired 105 shares of Cumberland Pharmaceuticals stock. The shares were purchased at an average price of $2.73 per share, with a total value of $286.65.

NASDAQ:CPIX opened at $3.18 on Friday. Cumberland Pharmaceuticals Inc. has a 12 month low of $2.58 and a 12 month high of $3.94. The business’s 50 day moving average price is $2.91. The company has a current ratio of 2.16, a quick ratio of 1.72 and a debt-to-equity ratio of 0.32. The stock has a market cap of $47.86 million, a price-to-earnings ratio of -22.71 and a beta of 0.23.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Monday, May 10th. The specialty pharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.14. Cumberland Pharmaceuticals had a positive return on equity of 3.75% and a negative net margin of 5.34%.

Several equities research analysts have commented on the company. B. Riley reiterated a “buy” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, March 22nd. Zacks Investment Research upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Tuesday, May 25th.

Several hedge funds have recently bought and sold shares of the company. Morgan Stanley grew its position in shares of Cumberland Pharmaceuticals by 131.3% in the first quarter. Morgan Stanley now owns 11,160 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 6,335 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cumberland Pharmaceuticals in the first quarter valued at approximately $32,000. M Holdings Securities Inc. purchased a new stake in shares of Cumberland Pharmaceuticals in the first quarter valued at approximately $33,000. Citadel Advisors LLC purchased a new stake in shares of Cumberland Pharmaceuticals in the first quarter valued at approximately $52,000. Finally, Sterling Financial Planning Inc. purchased a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter valued at approximately $65,000. Institutional investors and hedge funds own 21.44% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections.

Further Reading: Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.